Inmune Bio (INMB) EPS (Weighted Average and Diluted) (2021 - 2025)
Inmune Bio (INMB) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.18 as the latest value for Q4 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 55.0% to -$0.18 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.9 through Dec 2025, up 9.95% year-over-year, with the annual reading at -$1.86 for FY2025, 11.85% up from the prior year.
- EPS (Weighted Average and Diluted) hit -$0.18 in Q4 2025 for Inmune Bio, up from -$0.24 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.18 in Q4 2025 to a low of -$1.05 in Q2 2025.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.46 across 5 years, with a median of -$0.42 in 2022.
- Biggest YoY gain for EPS (Weighted Average and Diluted) was 60.0% in 2025; the steepest drop was 110.0% in 2025.
- Year by year, EPS (Weighted Average and Diluted) stood at -$0.56 in 2021, then soared by 43.78% to -$0.31 in 2022, then tumbled by 49.34% to -$0.47 in 2023, then increased by 14.89% to -$0.4 in 2024, then skyrocketed by 55.0% to -$0.18 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for INMB at -$0.18 in Q4 2025, -$0.24 in Q3 2025, and -$1.05 in Q2 2025.